{"id":"W4406775014","doi":"10.1002/ajh.27539","title":"Efficacy and Safety Results With Rilzabrutinib, an Oral Bruton Tyrosine Kinase Inhibitor, in Patients With Immune Thrombocytopenia: Phase 2 Part B Study","year":2025,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Chugai Pharmaceutical; Genentech; Grifols; AOP Orphan; Novo Nordisk; Argenx; Regeneron Pharmaceuticals; Bristol-Myers Squibb; CSL Behring; Celgene; CTI Biopharma; Swedish Orphan Biovitrum; Apellis Pharmaceuticals; BioCryst; Alnylam Pharmaceuticals; Sanofi; Alexion Pharmaceuticals; Amgen; Pfizer","keywords":"Immune thrombocytopenia; Bruton's tyrosine kinase; Medicine; Tyrosine-kinase inhibitor; Internal medicine; Tyrosine kinase; Immunology; Gastroenterology; Antibody; Receptor; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007489205,0.0002608682,0.001490209,0.0004291053,0.00008334142,0.00002262403,0.000199021,0.0000616276,0.00001806341],"category_scores_gemma":[0.0002957728,0.0001699671,0.00004277091,0.0008463829,0.0008250462,0.0001712299,0.0001030738,0.0005480723,0.000002214377],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001322236,"about_ca_system_score_gemma":0.003285152,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005031623,"about_ca_topic_score_gemma":0.0001926242,"domain_scores_codex":[0.9972662,0.0003647331,0.001014788,0.0003889647,0.0004977857,0.000467475],"domain_scores_gemma":[0.9980249,0.0003161364,0.0005307674,0.0004903265,0.0003842548,0.0002536596],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4183774,0.02623699,0.4939217,0.0002214529,0.001478007,0.00809416,0.003822013,0.00007038039,0.0003829245,0.0003212791,0.0008236197,0.04625006],"study_design_scores_gemma":[0.4877947,0.08678254,0.4143286,0.001376448,0.0004893985,0.002491329,0.003462404,0.0001566766,0.00170071,0.000015872,0.001032571,0.0003687283],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9978606,0.0002500329,0.00004792497,0.0007348005,0.00007840488,0.0008207136,0.000007817747,0.00001456883,0.0001850977],"genre_scores_gemma":[0.999083,0.00003378678,0.0005926582,0.0001583693,0.00003778136,0.000007694226,0.0000152641,0.0000276522,0.00004383911],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07959303,"threshold_uncertainty_score":0.6931055,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01100729598929618,"score_gpt":0.3249805975566005,"score_spread":0.3139733015673044,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}